Evaluation of azithromycin or hydroxychloroquine plus azithromycin combination therapy on cardiac conduction and function in guinea pigs

Xiang Li, Weijiang Tan, Shuang Zheng, Huan Sun, Xiaoshen Zhang, Xiaohui Li, Honghua Chen, Xuecong Ren, Tianzhen He, Caiyi Zhu, Yu Zhang, Feng YangbioRxiv 2020 · DOI

TL;DR

This study investigated the cardiac safety of azithromycin (AZM) and hydroxychloroquine (HCQ), alone and in combination, in guinea pigs. The findings indicate that AZM significantly prolongs the QT interval and impairs cardiac function, while the HCQ+AZM combination exacerbates cardiac dysfunction compared to HCQ alone.

What Problem Does This Paper Address?

During the early stages of the COVID-19 pandemic, hydroxychloroquine (HCQ) and azithromycin (AZM) were widely explored as potential treatments. However, concerns arose regarding their cardiotoxicity, with conflicting results from clinical trials and observational studies. To address this uncertainty and re-evaluate the safety profiles of these drugs, especially for non-COVID-19 applications, this research aimed to assess the impact of short-term AZM or HCQ + AZM treatment on cardiac conduction and function in a preclinical animal model. This is crucial for understanding potential risks and informing safe drug usage.

Methods

The study utilized a preclinical animal model, employing 32 male guinea pigs randomly assigned to four groups: control (CON), azithromycin (AZM) alone, hydroxychloroquine (HCQ) alone, and a combination of HCQ + AZM. Over a 9-day period, the animals received daily drug administrations.

Key techniques included:

  • Electrocardiography (ECG): Used to monitor cardiac electrical activity. Specifically, the study focused on parameters like the QT interval (reflecting ventricular repolarization), RR interval (heart rate), PR interval (atrial-ventricular conduction), and QRS duration (ventricular depolarization). A critical aspect was the evaluation and selection of the most appropriate QT interval correction formula (Van de Water's method was chosen for its superior correlation) to account for heart rate variations.
  • Transthoracic Echocardiography: Employed to assess cardiac morphology and function. This involved measuring left ventricular dimensions (diastolic and systolic), posterior wall thickness, end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (LVEF), and fractional shortening (LVFS).

These methods allowed for a comprehensive evaluation of both the electrical and mechanical aspects of cardiac health.

Datasets

Not discussed in the paper. The study utilized data collected from the experimental guinea pig model.

Key Insights and Ideas

  • AZM's Independent Cardiac Risk: The study strongly suggests that azithromycin, even when used alone, poses a significant risk to cardiac health by prolonging the QT interval and reducing left ventricular ejection fraction and fractional shortening. This highlights that AZM's cardiotoxicity is not solely dependent on its combination with HCQ.
  • Synergistic Cardiotoxicity of HCQ + AZM: The combination therapy of HCQ and AZM demonstrated a more pronounced negative impact on cardiac function than HCQ alone. This suggests a potential synergistic or additive cardiotoxic effect when these drugs are administered together, increasing the risk of cardiac dysfunction.
  • HCQ's Limited Acute Cardiotoxicity in Healthy Animals: In healthy guinea pigs, short-term HCQ monotherapy did not significantly alter QT interval or cardiac function parameters. This finding aligns with some previous studies but contrasts with observations in COVID-19 patients, hinting that underlying disease conditions might exacerbate HCQ's cardiac risks.
  • Importance of Preclinical Models for Drug Safety: The study underscores the value of preclinical animal models in identifying potential cardiotoxic effects of drugs before they are widely used in humans, especially when clinical data is conflicting or limited.

Key Results

  • QT Interval Prolongation: Both AZM and HCQ + AZM treatments significantly increased the corrected QT (QTc) interval on days 3, 6, and 9 compared to the control group. HCQ alone did not significantly affect the QTc interval.
  • Cardiac Function Impairment:
    • AZM treatment significantly decreased LVEF and LVFS on days 3, 6, and 9.
  • HCQ + AZM treatment significantly decreased LVEF and LVFS only on day 9.
  • Compared to CON, AZM and HCQ alone decreased EDV.
  • Compared to HCQ alone, HCQ + AZM treatment increased ESV on day 9.
  • Heart Rate: AZM decreased heart rates on day 9, while HCQ + AZM decreased heart rates on days 3, 6, and 9.
  • Conduction: AZM prolonged the PR interval. The HCQ + AZM treatment also affected PR interval on day 6. QRS complex durations remained largely unaffected across groups.

Limitations and Future Work

The authors acknowledge the following limitations:

  • Single Dose Study: The study explored the effects of AZM and HCQ + AZM at a single dose. Future research should investigate a range of doses (higher and lower) to fully understand the dose-dependent cardiotoxicity.
  • Healthy Animal Model: The study used healthy guinea pigs. To better mimic the conditions in COVID-19 patients, future studies could explore models that resemble SARS-CoV-2 induced cardiac damage, as disease-related cardiac injury might influence drug cardiotoxicity.

Promising future directions suggested include:

  • Molecular Mechanisms: Investigating protein expression alterations in cellular membrane receptors and their downstream signals to elucidate the underlying molecular mechanisms of cardiotoxicity.
  • Long-term Effects: Assessing the long-term cardiac effects of these drugs and their withdrawal.

Summary updated

Abstract

Abstract Background In the early stages of the coronavirus disease pandemic, the anti-malarial drug hydroxychloroquine (HCQ) and the antibiotic drug azithromycin (AZM) were widely used as emerging treatments. However, controversial cardiac toxicity results obtained from clinical trials and epidemic studies suggest that the cardiotoxicity of these two drugs should be re-evaluated. In the present study, we aimed to assess the impact of a short course of AZM or HCQ + AZM combination treatment on ECG and cardiac function in healthy guinea pigs. Methods Thirty-two male guinea pigs were randomly divided into four groups: control; AZM; HCQ; and HCQ + AZM groups. At 3, 6, and 9 days after treatment, electrocardiograms (ECGs) and echocardiographic techniques were used to determine important ECG parameters and cardiac functional parameters of the left ventricle (including posterior wall thickness, end systolic/end diastolic volume, ejection fraction, and fractional shortening). Results Although AZM decreased the heart rates of guinea pigs on day 9 (under anesthetized conditions), HCQ + AZM decreased heart rates on days 3, 6, and 9. The corrected QT intervals of guinea pigs after AZM and HCQ + AZM treatments were significantly increased, compared with CON and HCQ treatment respectively, on days 3, 6, and 9. However, QRS complex durations were not significantly different between the groups. AZM significantly decreased left ventricular ejection fraction (LVEF) and left ventricular fraction shortening (LVFS) on days 3, 6, and 9, whereas HCQ + AZM only decreased LVEF and LVFS on day 9. Posterior wall thickness and of the left ventricle in the diastolic and systolic states were not significantly different between these groups. In addition, compared with CON, AZM and HCQ decreased the EDV. And, in comparison with HCQ treatment, HCQ + AZM treatment increased ESV on day 9. Conclusions According to our study, AZM significantly prolongs the QT interval and damages cardiac function. Moreover, HCQ + AZM treatment increased the risk of cardiac dysfunction compared with HCQ treatment.
BibTeX
@misc{li2020evaluation,
  author = {Xiang Li and Weijiang Tan and Shuang Zheng and Huan Sun and Xiaoshen Zhang and Xiaohui Li and Honghua Chen and Xuecong Ren and Tianzhen He and Caiyi Zhu and Yu Zhang and Feng Yang},
  title = {{Evaluation of azithromycin or hydroxychloroquine plus azithromycin combination therapy on cardiac conduction and function in guinea pigs}},
  year = {2020},
  doi = {10.1101/2020.10.31.362566},
  howpublished = {bioRxiv},
}
Figure